Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months

BACKGROUND: The BRAF K601E mutation occurs in 5% of patients with melanoma, and is the third most common type of BRAF mutation. However, treatment with BRAF and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors is only approved in patients with BRAF V600-positive melanoma, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Marconcini, Riccardo, Galli, Luca, Antonuzzo, Andrea, Bursi, Simona, Roncella, Claudia, Fontanini, Gabriella, Sensi, Elisa, Falcone, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361706/
https://www.ncbi.nlm.nih.gov/pubmed/28344857
http://dx.doi.org/10.1186/s40164-017-0067-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361706/
https://www.ncbi.nlm.nih.gov/pubmed/28344857
http://dx.doi.org/10.1186/s40164-017-0067-4

Ejemplares similares